Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

270 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group.
Cavagna L, Nuño L, Scirè CA, Govoni M, Longo FJ, Franceschini F, Neri R, Castañeda S, Sifuentes Giraldo WA, Caporali R, Iannone F, Fusaro E, Paolazzi G, Pellerito R, Schwarting A, Saketkoo LA, Ortego-Centeno N, Quartuccio L, Bartoloni E, Specker C, Pina Murcia T, La Corte R, Furini F, Foschi V, Bachiller Corral J, Airò P, Cavazzana I, Martínez-Barrio J, Hinojosa M, Giannini M, Barsotti S, Menke J, Triantafyllias K, Vitetta R, Russo A, Bogliolo L, Bajocchi G, Bravi E, Barausse G, Bortolotti R, Selmi C, Parisi S, Salaffi F, Montecucco C, González-Gay MA; AENEAS (American and European NEtwork of Antisynthetase Syndrome) Collaborative Group. Cavagna L, et al. Among authors: quartuccio l. Clin Rev Allergy Immunol. 2017 Feb;52(1):71-80. doi: 10.1007/s12016-016-8528-9. Clin Rev Allergy Immunol. 2017. PMID: 26782036 Review.
Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
Quartuccio L, Fabris M, Salvin S, Atzeni F, Saracco M, Benucci M, Cimmino M, Morassi P, Masolini P, Pellerito R, Cutolo M, Puttini PS, De Vita S. Quartuccio L, et al. Rheumatology (Oxford). 2009 Dec;48(12):1557-9. doi: 10.1093/rheumatology/kep314. Epub 2009 Sep 29. Rheumatology (Oxford). 2009. PMID: 19789202
The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis.
Fabris M, Quartuccio L, Lombardi S, Saracco M, Atzeni F, Carletto A, Cimmino M, Fabro C, Pontarini E, Pellerito R, Bambara LM, Sarzi-Puttini P, Cutolo M, Manfredi M, Benucci M, Morassi P, Fischetti F, Padovan M, Govoni M, Curcio F, Tonutti E, De Vita S. Fabris M, et al. Among authors: quartuccio l. Autoimmun Rev. 2012 Mar;11(5):315-20. doi: 10.1016/j.autrev.2010.06.012. Epub 2010 Oct 23. Autoimmun Rev. 2012. PMID: 20974296
Chlamydophila psittaci subclinical infection in chronic polyarthritis.
Fabris M, De Vita S, Pasini E, Quartuccio L, Pontarini E, Lombardi S, Fabro C, Sarzi-Puttini P, Pellerito R, Benucci M, Morassi P, Biasi D, Curcio F, Dolcetti R. Fabris M, et al. Among authors: quartuccio l. Clin Exp Rheumatol. 2011 Nov-Dec;29(6):977-82. Epub 2011 Dec 22. Clin Exp Rheumatol. 2011. PMID: 22153301
The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers.
Fabris M, Quartuccio L, Vital E, Pontarini E, Salvin S, Fabro C, Zabotti A, Benucci M, Manfredi M, Ravagnani V, Biasi D, Atzeni F, Sarzi-Puttini P, Morassi P, Fischetti F, Bazzicchi L, Saracco M, Pellerito R, Cimmino M, Carraro V, Semeraro A, Schiavon F, Caporali R, Bortolotti R, Govoni M, Fogolari F, Tonutti E, Bombardieri S, Emery P, De Vita S. Fabris M, et al. Among authors: quartuccio l. Arthritis Rheum. 2013 Jan;65(1):88-97. doi: 10.1002/art.37707. Arthritis Rheum. 2013. PMID: 23001900 Free article.
The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study.
Quartuccio L, Fabris M, Pontarini E, Salvin S, Zabotti A, Benucci M, Manfredi M, Biasi D, Ravagnani V, Atzeni F, Sarzi-Puttini P, Morassi P, Fischetti F, Tomietto P, Bazzichi L, Saracco M, Pellerito R, Cimmino M, Schiavon F, Carraro V, Semeraro A, Caporali R, Cavagna L, Bortolotti R, Paolazzi G, Govoni M, Bombardieri S, De Vita S. Quartuccio L, et al. Ann Rheum Dis. 2014 Apr;73(4):716-21. doi: 10.1136/annrheumdis-2012-202435. Epub 2013 Mar 16. Ann Rheum Dis. 2014. PMID: 23505228
Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritides.
Govoni M, Bortoluzzi A, Lo Monaco A, Adami S, Addimanda O, Caimmi C, De Vita S, Ferri C, Manfredi A, Orsolini G, Possemato N, Quartuccio L, Salvarani C, Zabotti A, Rossini M. Govoni M, et al. Among authors: quartuccio l. Adv Ther. 2014 Aug;31(8):780-802. doi: 10.1007/s12325-014-0142-8. Epub 2014 Aug 12. Adv Ther. 2014. PMID: 25112460 Review.
Myositis in primary Sjögren's syndrome: data from a multicentre cohort.
Colafrancesco S, Priori R, Gattamelata A, Picarelli G, Minniti A, Brancatisano F, D'Amati G, Giordano C, Cerbelli B, Maset M, Quartuccio L, Bartoloni E, Carubbi F, Cipriani P, Baldini C, Luciano N, De Vita S, Gerli R, Giacomelli R, Bombardieri S, Valesini G. Colafrancesco S, et al. Among authors: quartuccio l. Clin Exp Rheumatol. 2015 Jul-Aug;33(4):457-64. Epub 2015 Jun 19. Clin Exp Rheumatol. 2015. PMID: 26088683
270 results